Introduction
Multiple sclerosis (MS) is most common in Caucasian populations. A few studies have attempted to examine MS in ethnic minority (EM) groups but have struggled to make effective comparisons because of small patient numbers, lack of comparative data, limited follow-up and additional confounding factors. In addition, analysis [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] has focused on early phases of disease [1] , cross-sectional analysis [2, [8] [9] [10] or specific subgroups [3, 5] . Few have examined long-term outcomes [4, 6, 7] , and none of these has compared with a geographically matched Caucasian population. However, differences in disease frequency and phenotype may provide key insights into disease aetiology and disease trajectory. Patterns of early disease and long-term outcomes were examined in EM and Caucasian patients from a well-described populationbased cohort from the UK.
Methods

Patient selection
The southeast Wales MS registry was established in 1985 from a cross-sectional study [11] with prospective longitudinal data collected since 1999. Patients were included if they had a diagnosis of MS, ethnicity was recorded, and prospectively collected longitudinal data were available from disease onset, including relapses, disease course and Expanded Disability Status Scale (EDSS) [12] scores. EM patients were also classified by place of birth. The South East Wales Ethics Committee approved the study (reference number 05/ WSE03/111) and written informed consent was obtained from all patients.
Statistical analysis
Demographics and clinical features at disease onset were compared using chi-squared tests, Student's t test and one-way ANOVA. Time to EDSS 3.0, 4.0 and 6.0 was analysed using Cox proportional hazards regression, adjusting for age at onset, sex and initial disease course. All analyses were undertaken using SPSS version 21 (IBM Corporation, Armonk, NY, USA).
Results
Demographics and clinical features
In total, 1866 Caucasian patients and 83 EM patients were identified (22 Afro-Caribbean, 48 Asian and 13 Middle Eastern, Table S1 ). 27 EM patients were born in Europe and 35 elsewhere. Country of birth was not available in 21.
The male:female ratio was similar in both groups (EM 1.7:1, Caucasian 2.3:1, P = 0.10). EM patients were younger at disease onset (28.6 years vs. 32.8 years, P = 0.001). There was no difference in demographic features between EM subgroups or by country of birth.
Primary progressive MS was less common in EM patients (EM 4.8%, Caucasian 11.6%, P = 0.03).There was no difference in annualized relapse rates (EM 0.65, Caucasian 0.55, P = 0.08) or for symptoms at disease onset (Fig. 1) . No difference was identified for any clinical features between EM subgroups or by country of birth. 
Discussion
In this study a younger age at onset and reduced frequency of primary progressive MS has been identified in EM patients, with no differences observed in other presenting features. Differences in reaching EDSS 3.0 and EDSS 4.0 by ethnicity were also identified, although this effect did not persist in later stages of disease.
The reason for the difference in outcomes is not clear, but could be genetic or environmental, or a combination of the two. It may also reflect variation in socioeconomic status, particularly for immigrants. The fact that the differences seen were limited to the earlier phases of disease is intriguing, although larger studies are needed to confirm whether this was a power limitation at EDSS 6. Early studies suggested a poorer outcome for African Americans with MS [1, 2, 5] , but these studies were limited by cross-sectional analysis methods and the inclusion of patients with optico-spinal MS before neuromyelitis optica was recognized as a separate disease. More recent studies have found a time to EDSS 6.0 of 22 years in Hong Kong Chinese [6] , 25 years in Lebanese [4] and 26 years in Brazilian patients [7] , which are at the upper end of estimates in Caucasian populations [13] . Additionally a recent comparative study of Japanese and British patients with MS has shown a reduced frequency of primary progressive MS and a lower MS severity score in Japanese patients, implying a better outcome than in British patients [10] .
Limitations of our study included the inability to examine outcomes in specific ethnic subgroups as a result of limited patient numbers, the representation of only three EM groups and the lack of detailed long-term outcomes at very high disability score (i.e. EDSS 8.0 and death) which may have been informative. Defining differences in outcomes would clearly be of value in informing patient management in EM but is only likely to be achieved by the interrogation of very large combined datasets and would be an important future direction of research. In addition future studies may benefit from more detailed data on family ancestry and geographical origin which would also allow reflection on the potential for genetic admixing with different European populations, particularly those of Afro-Caribbean descent.
In conclusion, our study suggests that presenting features for patients with MS residing in a common geographical location is similar across ethnic groups. However, EM patients present earlier and accumulate early disability more rapidly than their Caucasian counterparts. These observations may be of importance for disease management in EM patients, in particular when considering early efficacy of disease-modifying therapies.
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